Clerk of the House of Representatives Socretary of the Senate Legislative Resource Center Office of Public Records Legislative Resource Center B-106 Cannon Building Washington, DC 20515

232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Fliers Are Required To Complete This Page

E. Registrant Name	······································	
Skadden, Arps, Slate, Meagher & Flom	LLP	
0.00		
2. Address		
1440 New York Avenue, N.W. Washington	n, D.C. 20005	
). Principal Place of Business (if different from line 2)	•	
	Zip (or Country)	
6. Cossact Name Telephone.  James A. Losey (202) 371-76	E-mail (optional) BOO	5. Senate 10 # 35560-191
daties A. Hosey (202) 311-1		
7. Client Name  Self		6, House ID 0
Glaxo Wellcome, Inc.		31706025
INCOME OR EXPENSES . Complete Eithe	r Line 12 OR Line 13	1411
INCOME OR EAFENSES. Complete Esthe	TLANC 12 OK LANC 13	1417-7-1-1
12. Lobbying Firms	13. Orga	nizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying period were:	activities for this reporting
Less than \$10,000 🔲	Less than \$10,000 🚨	•
\$19,000 or more 🔯 💠 \$ 20,000	\$19,000 or more 🔲 🗆 \$	
\$10,000 or more  so \$ 20,000 become (nearest \$20,000)  Provide a good faith estimate, rounded to the hearest \$20,000,	14. REPORTING METHOD. accounting method. See instruction	
of all lobbying related income from the client (including all	Method A. Reporting amoun	ets using LDA definitions only
payments to the registrant by any other entity for lobbying activities on behalf of the client).	Method B. Reporting amous	
	Method C. Reporting amous laternal Revenue	ets under section 162(e) of the
1. 1 1.		:
ignature James G. Long	<u> </u>	
rinted Name and Title JAMES 4.	LOSEY PARTNE	<u>e</u>
0.3(REV 6/98)	1	: PAGE Lot <u>4</u>
•		
·		}

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant negated in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.  15. General issue area codeRCR	LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.  15. General issue area codeHCR	News Chaddon 3mm	Client Name	Glaxo Wellcome, Inc.	
Ingaged in lobbying on behalf of the client during the reporting period. Using a separate page for each come, provide information as requested. Attach additional page(s) as needed.  15. General issue area code   HCR   (one per page)  16. Specific lobbying issues  Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Motored-dose inhalers, as well as national regulatory actions regarding same issue.  17. House(s) of Congress and Federal agencies contacted   Check if None   U.S. House of Representatives   U.S. Senate   Environmental Protection Agency   Department of State    18. Name of cach individual who acted as a lobbyist in this issue area   Name   Covered Official Position (if applicable)   Names   A. Losey, Partner   Covered Official Position (if applicable)   Names   A. Losey, Partner   Covered Official Position (if applicable)   Check if None   Ch	ingaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.  15. General issue area code   HCR   (one per page)  16. Specific lobbying issues  Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Metered-dose inhalers, as well as national regulatory actions regarding same issue.  17. House of Representatives U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  18. Name of cach individual who acted as a lobbyist in this issue area  Name   Covered Official Position (if applicable)   Name  James A. Losey, Partner   Covered Official Position (if applicable)	-			
16. Specific lobbying issues	16. Specific lobbying issues  Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Motered-dose inhalers, as well as national regulatory actions regarding same issue.  17. House(s) of Congress and Federal agencies contacted  U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  18. Name of cach individual who acted as a lobbyist in this issue area  Name  Covered Official Position (of applicable)  I Mannes A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above  Claxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature  Date	neaged in lobbying on behalf of the client during t	he reporting pe	reflect the general issue areas in which criod. Using a separate page for each	the registrant code, provide
Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Motered-dose inhalers, as well as national regulatory actions regarding same issue.  17. House(s) of Congress and Federal agencies contacted	Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Metered-dose inhalers, as well as national regulatory actions regarding same issue.  17. House(s) of Congress and Federal agencies contacted  U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  18. Name of each individual who acted as a lobbyist in this issue area  Name  Covered Official Position (if applicable)  James A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome, Inc. owned by Glaxo Wellcome, FEC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature  Date  Date	5. General issue area code HCR (one per	r page)		:
Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Motered-dose inhalers, as well as national regulatory actions regarding same issue.  17. House(s) of Congress and Federal agencies contacted	Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the Metered-dose inhalers, as well as national regulatory actions regarding same issue.  17. House(s) of Congress and Federal agencies contacted	16. Specific lobbying issues			
House(s) of Congress and Federal agencies contacted	House(s) of Congress and Federal agencies contacted		_		
U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  18. Name of each individual who acted as a lobbyist in this issue area  Name Covered Official Position (if applicable)  James A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Mellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature Date Date	U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  [8. Name of cach individual who acted as a lobbyist in this issue area    Name   Covered Official Position (if applicable)	- <b>-</b>	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		1
U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  18. Name of each individual who acted as a lobbyist in this issue area  Name Covered Official Position (if applicable)  James A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Mellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature Date Date	U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  [8. Name of cach individual who acted as a lobbyist in this issue area    Name   Covered Official Position (if applicable)				
U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State  [8. Name of each individual who acted as a lobbyist in this issue area    Name   Covered Official Position (if applicable)   Name	U.S. House of Representatives U.S. Senate Environmental Protection Agency Department of State    Name of each individual who acted as a lobbyist in this issue area    Name   Covered Official Position (of applicable)   Name	7 House(s) of Congress and Federal agencies on	ntacted	Check if None	
Environmental Protection Agency Department of State  18. Name of cach individual who acted as a lobbyist in this issue area  Name Covered Official Position (if applicable)  No.  James A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature  Date  Date	Environmental Protection Agency Department of State  8. Name of each individual who acted as a lobbyist in this issue area  Name Covered Official Position (of applicable)  James A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above  Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature  Date	U.S. House of Representatives			
8. Name of each individual who acted as a lobbyist in this issue area    Name	8. Name of each individual who acted as a lobbyist in this issue area    Name   Covered Official Position (6f applicable)   Name	Environmental Protection Agency			
Name  James A. Losey, Partner  James A. Losey, Partner  Discovered Official Position (if applicable)  No. 10. Interest of each foreign entity in the specific issues listed on line 16 above  Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature  Date  Printed Name and Title	James A. Losey, Partner  James A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above  Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature  Date  Date	Department of State			
James A. Losey, Partner  19. Interest of each foreign entity in the specific issues listed on line 16 above. Check if None  Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature Date  Printed Name and Title	James A. Losey, Partner  James A. Losey, Partner  Discontinuous description of the specific issues listed on time 16 above	8. Name of each individual who acted as a lobby	ist in this issue	e area	
James A. Losey, Partner    James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James A. Losey, Partner   James Lo	James A. Losey, Partner    Date   Dat	Name.		Covered Official Position (if applicable	
19. Interest of each foreign entity in the specific issues listed on line 16 above. Check if None Glazo Wellcome, Inc. owned by Glazo Wellcome, FLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature Date  Printed Name and Title	19. Interest of each foreign entity in the specific issues fisted on line 16 above	James A. Losey, Partner		11-14-14-11	10
19. Interest of each foreign entity in the specific issues listed on line 16 above	19. Interest of each foreign entity in the specific issues fisted on line 16 above	IMINA			
19. Interest of each foreign entity in the specific issues fisted on line 16 above	19. Interest of each foreign entity in the specific issues listed on line 16 above.   Check if None  Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MbIs that protect patients and physician access to essential medical treatment options.  Signature Date				
19. Interest of each foreign entity in the specific issues listed on line 16 above	19. Interest of each foreign entity in the specific issues listed on line 16 above				
19. Interest of each foreign entity in the specific issues listed on line 16 above	19. Interest of each foreign entity in the specific issues listed on line 16 above				Q
19. Interest of each foreign entity in the specific issues fisted on line 16 above	19. Interest of each foreign entity in the specific issues fisted on line 16 above				j
Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature Date  Printed Name and Title	Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.  Signature			•	
Printed Name and Title		Glaxo Wellcome, Inc. owned by Gla the U.S. and abroad and seeks to patients and physician access to	exo Wellcom ensure tra essential	e, PLC sells pharmaceutical nsition policy for MDIs tha medical treatment options.	t protect
	Printed Name and Title				3
	•	Printed Name and Title			
Page 2 of 4	Name LD-2 (Hev 6/98)	Name L30-2 (Rev 6/98)		•	Page 2 of 4

		and the share and in which the	repistrant	
OBBYING ACTIVITY.	Select as many codes as nece	essary to reflect the general issue areas in which the	to browide	
ngaged in lobbying on beha	df of the client during the rep	porting period. Using a separate page for each cod	ne, provide	
formation as requested. A	ttach additional page(s) as n	ecátó.		
	ENV (one per page	۵۱	•	
<ol><li>General issue area code</li></ol>	Esto (otte bei beite	×1	ł.	
C. C	_		· }	
<ol><li>Specific lobbying issues</li></ol>	•			
Efforts regardit	ig US government pos	ition on the Montreal Protocol	:	
"transition stra	stegy" for the meter	ed-dose inhalers, as well as	<u> </u>	
national regulat	tory actions regardí:	ng same issue.		
•				
			:	
7 Houselsh of Congress of	nd Federal agencies contacte	ed Check if None		
U. Morracial of Crafficas a	ne remitte aboutains commen			٠
U.S. House of Re	epresentatives		`	
U.S. Senate				
	rotection Agency			
Department of St	• •	•		
			:	
18. Name of each individu	al who acted as a lobbyist in	this issue area		
,	-		į - ;	i
	Name	Covered Official Position (of applicable)		١,
			\$	Ĺ
James A. Losev.	Partner		,:	
	(			
				ļ
				ļ
				Ì۳.
			•	ĺ
				T,
•			•	Į
			<u>:</u>	Ľ
	· · · · · · · · · · · · · · · · · · ·		İ	ļ
				-∤
		1		,
		ed on line 16 above	ļ	
	entity in the specific issues liste		٠.	
19. Interest of each intergit of	THA ALMAN NO CITYA	Wellcome, PLC, sells pharmaceutical		
Glaxo Wellcome,			hat prote	ect
Glaxo Wellcome, in the U.S. and	abroad and seeks to	ensure transition policy for MDIs t		
Glaxo Wellcome, in the U.S. and	abroad and seeks to sician access to ess	ential medical treatment options.		
Glaxo Wellcome, in the U.S. and	abroad and seeks to sician access to ess		: <b>-</b>	
Glaxo Wellcome, in the U.S. and patient and phys	abroad and seeks to sician access to ess	ential medical treatment options.  Date 8/12/99	· ·	
Glaxo Wellcome, in the U.S. and patient and phys	abroad and seeks to sician access to ess	ential medical treatment options.  Date 8/12/99		
Glaxo Wellcome, in the U.S. and patient and phys Signature	abroad and seeks to sician access to ess	ential medical treatment options.  Date 8/12/99  ther		
Glaxo Wellcome, in the U.S. and patient and phys Signature	abroad and seeks to sician access to ess	ential medical treatment options.  Date 8/12/99  ther		
Glaxo Wellcome, in the U.S. and patient and phys Signature	abroad and seeks to sician access to ess	ential medical treatment options.  Date 8/12/99  ther		 •

Client new address				
1. Client new principal place of bas		WERRELEWINE CO. C.	PROPERTY LONGON PROPERTY INC.	
City		/Zip (or Country)		
22. New general description of cities				
LOBBYIST UPDATE  3. Name of each previously  Robert E. Lig		longer expected to act as a lobby	ist for the client	
ISSUE UPDATE  14. General lobbying issues process  FFILIATED ORGANIZ  15. Add the following affiliar		niger pertain		
Name		Address Principal Place of Busin		usin <del>es</del> s
			(city and state or o	ountry)
·	:			
	reported organization that is	so longer affiliated with the regis	trant or client	
FOREIGN ENTITIES 7. Add the following foreign		tso longer affiliated with the regis	trant or client	:
26. Name of each previously FOREIGN ENTITIES 27. Add the following foreign Name		Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage to client
FOREIGN ENTITIES 7. Add the following foreign Name	n entities Address	Princepal place of business	Amount of contribution for lobbying activities	percentage in chent
FOREIGN ENTITIES 7. Add the following foreign Name 28 Name of each previously affiliated organization	Address Address reported foreign entity that n	Principal place of business (city and stable or country)	Arrows of contribution for lobbying activities	cisent cisent ant, client or